Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection and Monitoring

Abstract

Listen

Translate article

Early detection and precise diagnosis of lung cancer are critical to select proper therapeutic treatments as early as possible. Toward this direction, the discovery and exploitation of novel innovative, non-invasive, and reliable tumor biomarkers are of vital importance. In this review, we present emerging bloodbased molecular biomarkers that have been evaluated for the detection and A. Markou • I. Sourvinou • I. Balkouranidou • E.S. Lianidou (*) Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece e-mail: athina_markoy@yahoo.gr; jsourvin@gmail.com; ioannabalg@gmail.com; evilianidou@gmail.com # Springer Science+Business Media Dordrecht 2015 V.R. Preedy, V.B. Patel (eds.), Biomarkers in Cancer, Biomarkers in Disease: Methods, Discoveries and Applications, DOI 10.1007/978-94-007-7681-4_35 325 monitoring of lung cancer. We specially focus on biomarkers based on a non-invasive liquid biopsy approach, such as circulating tumor cells (CTCs), circulating miRNAs, gene promoter methylation, and DNA mutations in cellfree circulating DNA. List of Abbreviations 5-Aza-dC 5-Aza-20-deoxycytidine AD Adenocarcinoma ALK Anaplastic Lymphoma Kinase cfDNA Cell-Free DNA CTCs Circulating Tumor Cells DFI Disease-Free Interval EGFR Epidermal Growth Factor Receptor EGFR-TKIs EGFR Tyrosine Kinase Inhibitors LCM Laser Cell Microdissection miRNA MicroRNA MSP Methylation-Specific PCR NSCLC Non-small Cell Lung Cancer OS Overall Survival RT-qPCR Reverse Transcription Quantitative PCR SCC Squamous Cell Carcinoma SCLC Small-Cell Lung Cancer